Geoffrey J. Gorse MD

Infectious Disease•Saint Louis, MO

Professor, Internal Medicine, St Louis University School of Medicine

Join to View Full Profile

1225 S Grand BlvdSaint Louis, MO 63104
Phone+1 314-577-8000
Fax+1 314-977-9196

Education & Training

University of California (Irvine)Fellowship, Infectious Disease, 1981 - 1983
University of California (Irvine)Fellowship, Infectious Disease, 1980 - 1981
University of California (San Francisco)/FresnoResidency, Internal Medicine, 1977 - 1980
David Geffen School of Medicine at UCLAClass of 1977

Certifications & Licensure

CA State Medical License 1978 - 2026
MO State Medical License 1989 - 2026
WV State Medical License 1983 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)
Completed
Phase 1
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine
Withdrawn
A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult Volunteers
Completed
Phase 2
A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Completed
Phase 1
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Completed
Phase 1
Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults
Completed
Phase 1
Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults Start of enrollment: 2007 Apr 01
Completed
Phase 1
MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly Start of enrollment: 2012 Oct 01
Withdrawn
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Preschool-Aged Household Contacts as a Risk Factor for Viral Respiratory Infections in Healthcare Personnel.
Zachary M Most, Ann-Christine Nyquist, Lewis J Radonovich, Maria C Rodriguez-Barradas, Connie Savor Price
Open Forum Infectious Diseases. 2023-02-01
1 citations
MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity o...
Geoffrey J Gorse, Stephen Grimes, Helen Buck, Hussain Mulla, Peter White
Vaccine. 2022-03-01
6 citations
A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
Geoffrey J Gorse, Stephen Grimes, Helen Buck, Hussain Mulla, Peter White
Vaccine. 2022-02-23

Press Mentions

Enhanced Flu Protection: Four Beats ThreeMarch 13th, 2015
Quadrivalent vs. Trivalent Flu Vaccines Comparing Responses to B StrainsMarch 13th, 2015